Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis

  • In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1
  • Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1  
/by
Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List

Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List
metzgma4

/by
What’s next in Neuroscience drug discovery

What’s next in Neuroscience drug discovery
hajdola1

/by
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
arcticnovartis

  • New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland
  • Approximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees
  • Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients

Basel, February 6, 2026 – Novartis today broke grou

/by
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline

Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

Geschäftsjahr

/by
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Full year

/by
How Novartis is helping to eliminate leprosy

How Novartis is helping to eliminate leprosy
imberje1

/by
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis

  • Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1

  • Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care

  • Novartis plans to submit to health authorities globally starting in early 2026
/by
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis

  • Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1

  • Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care

  • Novartis plans to submit to health authorities globally starting in early 2026
/by
Letter to global governments: A call for bold life sciences investment

Letter to global governments: A call for bold life sciences investment
angilma1

/by